StockData
Beam Therapeutics Inc. logo

Beam Therapeutics Inc. (BEAM) stock

BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)

Close on Nov 13, 2026Market cap $2.36BP/E –Yield –

Beam Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Beam Therapeutics's price to sales ratio was 17.1× on Nov 11, 2026, against 46.1× a year earlier. Over the last 5 years it ranged from 4.6× to 103.3×, with a median of 26.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202617.1×−33.4
2025Dec 31, 202550.4×+44.6
2024Dec 31, 20245.9×−20.6
2023Dec 29, 202326.5×−3.5
2022Dec 30, 202230.0×–

More Beam Therapeutics figures

See a number that looks wrong?